Axonyx Announces Completion of Treatment Segment of Phase II Alzheimer's Trial With Phenserine.Health/Medical Writers NEW YORK--(BW HealthWire)--Oct. 2, 2001 Axonyx (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AXYX) announced today that the patients currently enrolled in its Phase II trial evaluating the safety of Phenserine have completed the active treatment segment of the clinical trial. Phenserine is an acetylcholinesterase inhibitor acetylcholinesterase inhibitor n. See cholinesterase inhibitor. being developed by Axonyx for the treatment of Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. (AD). Patients are currently in the four-week washout washout to disperse or empty by flooding with water or other solvent. medullary solute washout a syndrome in which the relative hyperosmolarity of the renal medulla is reduced due to an excessive loss of sodium and chloride from phase, as specified in the clinical trial protocol A Clinical Trial Protocol is a document that describes the objective(s), design, methodology, statistical considerations, and organization of a clinical trial. The protocol usually also gives the background and reason the trial is being conducted, but these could be provided in . Results of the Phase II trial are expected to be announced To be announced (TBA) A contract for the purchase or sale of an MBS to be delivered at an agreed-upon future date but does not include a specified pool number and number of pools or precise amount to be delivered. within four to six weeks from today. Axonyx designed the trial to study Phenserine at therapeutic doses in Alzheimer's Disease patients in order to provide safety data as well as an indication of therapeutic efficacy. Based on these data and clinical judgment a decision will be made concerning Phenserine's potential therapeutic utility for the treatment of AD. In the current trial, patients with mild to moderate AD were randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. to a double blind, placebo-controlled trial. Two-thirds of the patients in the study received Phenserine and one-third received a placebo for 12 weeks; this treatment segment is being followed by 4 weeks when the patients will not receive any treatment. The study is being conducted, to Good Clinical Practice standards under an IND, in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. at five clinical sites well known for their work on AD therapies. Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the Securities and Exchange Commission, specifically Axonyx's Annual Report on Form 10-KSB, as amended. Among other things, Axonyx cannot assure that results of the Phase II trial will be announced within the expected time frame, or that such results, when announced, will indicate sufficient therapeutic efficacy so as to support further studies. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion